Photo credits: Phiogen

PHIOGEN, a Texas-based venture developing off-the-shelf live biotherapeutic products, is excited to share a handful of significant business milestones that have opened doors for future growth and collaboration. From prestigious program selections to high-profile presentations, PHIOGEN is making waves in the biotech community.

Selected for Springboard Enterprise Healthcare Accelerator and Networking Community

PHIOGEN was recently chosen for the highly competitive Springboard Enterprise Accelerator, a program that supports women-led life science companies. This platform is an incredible opportunity for the venture to expand its network within the pharmaceutical industry. The program’s connections, particularly with partners such as Eli Lilly, offer unique resources and possible pathways to collaboration.

As part of this selection, Amanda Burkardt, the company’s CEO, has been invited to attend the Springboard Annual Awards Gala in October where PHIOGEN and the other startups will be featured, held at the NASDAQ Market Site at Times Square in New York City, as well as pitching at JP Morgan HealthCare Conference 2025 in San Francisco.

Presentation at Texas Legislature Fall Policy Summit

In another exciting development, PHIOGEN has been selected to present at the Fall Policy Summit in front of Texas legislators. This distinction is awarded to only three companies across Texas, and PHIOGEN will have the opportunity to highlight its innovative journey in developing live biotherapeutic products and raising awareness for need for solutions to the growing AMR crisis.

Invited to Return to SXSW Pitch as Alumni

PHIOGEN was honored to be invited back to SXSW Pitch as alumni to share updates on the startup’s progress over the past year. Entrepreneurs will have the opportunity to share advances made since their last appearance and the next steps in their journey. This event will allow PHIOGEN to continue dialogues with investors and industry partners and share key insights gained from last year’s networking efforts.

Invited to Join the ARPA-H Network

The ARPA-H Investor Catalyst Hub (ICH) has welcomed PHIOGEN into a US government sponsored and invite only membership and innovation hub, marking a significant achievement for the company. This membership grants PHIOGEN access to cutting-edge ARPA-H programming and potential funding opportunities, further accelerating its growth in the healthcare sector.

Finalist in Boston Biotech Week 2024

PHIOGEN is one of eight finalists selected for the prestigious Biotech Innovation category at the Boston Biotech Week (BWB) Awards for 2024. This recognition places the company among top innovators in the biotech field and offers further networking opportunities at the annual BWB conference in Boston.

Lead Asset for Recurrent Urinary Tract Infections Progressing to Clinical Trials

In a significant R&D advancement, PHIOGEN has successfully progressed its lead asset through the final stages of pre-clinical development and is preparing for an IND submission with a primary indication of recurrent urinary tract infections. The company is now preparing to fundraise to advance this lead product into a Phase 1b/2a clinical trial next year, marking a crucial step in bringing their innovative live biotherapeutic products closer to market.

A post by PHIOGEN

Just like PHIOGEN, INCATE encourages all our ventures to share their exciting opportunities, connections, and milestones. We’d love to hear from you!
Reach out to us at comms@incate.net  and let us know what you’ve been up to.